- Home
-
About UsIntroduction History Quality Qualification
- Products
- Services
News-
202211-18
CelluPro's medium supports listing of first-in-class new drug TelitaciceptOn March 9, 2021, Chinese National Medical Products Administration (NMPA) approved RemeGen's ...
-
202211-18
CeluPro's medium supports listing of Chinese first self-developed ADC new drugOn June 9, 2021, Chinese National Medical Products Administration (NMPA) announced that Chinese...
- Contact Us
- Address：60 Beijing Middle Road, Economic & Technological Development Area, Yantai Municipality, Shandong Province, China
- CONTACT
- HR：Tel.：+86-535-3573399，Email：hr@cellupro.cn
- Sales department：Tel：+86-535-3573396，Email：sales@cellupro.cn
- Technical support：Tel：+86-535-3573480，Email：support@cellupro.cn
WeChat